Early Detection of HCV in Injection Drug Users

Launched by INSTITUTE OF HEALTH INFORMATION AND STATISTICS OF THE CZECH REPUBLIC · May 21, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Early Detection of HCV in Injection Drug Users," is focused on finding better ways to detect Hepatitis C virus (HCV) in people who use or have used injectable drugs. The research is being conducted in multiple centers across the Czech Republic and aims to develop and test new methods for screening individuals for HCV early on. This is important because early detection can lead to better treatment options and outcomes for patients.

To be eligible for this study, participants must be at least 18 years old and currently use or have previously used injecting drugs. The trial is currently recruiting participants of all genders. If someone chooses to join, they can expect to take part in a non-interventional study, meaning they will not receive any new treatments but will help researchers understand how to improve screening methods. Participation is voluntary, and individuals must agree to be part of the project to join. This study aims to improve the healthcare system's ability to identify and help those affected by Hepatitis C.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age 18+
• • an active injecting drug user or have used injecting drugs at any time in the past
• Exclusion Criteria:
• • not agreeing to participate in the project

Trial Officials